XIV Foresight Training Course

The health emergency: regulatory crash and future perspectives


This past year we have witnessed unprecedented responses to the COVID-19 emergency that led the scientific community to an unparalleled mobilisation and sharing of information between researchers, companies, regulators, healthcare professionals, patient representatives and public health bodies. This resulted in the approval of several vaccines and medicines against this new disease to get the pandemic under control.

The XIV Foresight Training Course (FTC) “The health emergency: regulatory crash and future perspectives” will run virtually on December 10th, 2021 at 11.15am (CET).

In particular, the first session of the event will be focused on the extraordinary regulatory measures put in place by the international and national authorities to face the emergency, the lessons learnt from the pandemic and their impact on future actions that might improve the healthcare system in Europe.

The European Medicines Agency (EMA) adapted its assessment procedures, by using the rolling review process, to achieve the authorisation of safe and effective treatments and vaccines for COVID-19 within the shortest possible time frame, as well as a rapid scientific advice procedure has been put in place.

In addition, conditional marketing authorisations have been granted by the European Commission (EC) to expedite the approval of treatments and vaccines, on the basis of available evidence as soon as it became available from ongoing studies.

Several challenges occurred in the clinical practice as well as in the conduct of clinical trials due to limitations in the access to healthcare facilities and trial staff availability. The Guidance on the management of clinical trials during the COVID-19 pandemic has been published in February 2021.

In this framework the use of innovative digital technologies, such as Electronic Medical Records, Health Apps and other medical devices, collecting health data regularly, has been widely enhanced. This can support the management and monitoring not only of COVID-19 patients but also other diseases. An insight on the value of the use and sharing of health data will be provided in the second and third sessions of the course.

What is left of all these changes? How will they influence the future?

Feel free to raise your questions to speakers in advance using the Slido link here.


Fedele Bonifazi, Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus

Introductory remarks

Maurizia Dossena & Enrico Bosone

Session 1 – How the European regulatory framework reacted to the COVID-19 emergency:
extraordinary and challenging measures

Chairs – Viviana Giannuzzi & Vincenzo Salvatore

Regulatory process in the COVID-19 era: how to deal with the organisational and scientific challenges at the European Medicines Agency level?
Fergus Sweeney, Clinical Studies and Manufacturing Task Force, European Medicines Agency

Clinical research after the COVID-19 era: the current scenario and the upcoming application
of the Clinical Trials Regulation
Martine Dehlinger-Kremer, ICON Plc & European CRO Federation (EUCROF)

Decentralized Clinical Trials: strengths and weaknesses of safety management
Maria Grazia Felisi, Consorzio per Valutazioni Biologiche e Farmacologiche

The opportunity of decentralized Clinical Trials in rare diseases: the PRONTO study
Stefano Portolano, Azafaros

Strengths and weaknesses of General Data Protection Regulation implementation for
paediatric research
Annagrazia Altavilla, Espace Ethique PACA-Corse/AP-HM

Panel discussion


Session 2 – Connecting and sharing health data: the repurposing approach 
Chairs – Fedele Bonifazi & Marek Migdal

The therapeutic value of drug repurposing and repositioning
Oscar Della Pasqua, University College London

Data Space and Regulatory Decision making
Ine Skottheim Rusten, The Norwegian Medicines Agency

Artificial Intelligence tool to predict drug efficacy and safety profile
Aris Persidis, Biovista

Health data collection and FAIRification
Marco Roos, Leiden University Medical Centre

Panel discussion


Session 3 – The power of data sharing to enhance evidence for innovative treatments
Chairs – Enrico Bosone & Paola Baiardi

Federated learning as a tool for gathering knowledge from multiple data sources
George Drosatos, Athena Research and Innovation Centre

European Reference Networks and patients’ registries initiative
Maurizio Scarpa, European Reference Network for Hereditary Metabolic Disorders – MetabERN

The Duchenne Data Platform
Nawel van Lin, Center for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center

Real-World Evidence Data in a Drug Submission Process: the EMA vs. FDA perspective
Luca Pani, University of Miami

Panel discussion

Collaborative networks against COVID-19: Lessons learned from LEOSS, NAPKON, ORCHESTRA
Jörg Janne Vehreschild, University Hospital of Cologne

Real use of real-world data
Fedele Bonifazi, Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus

Panel discussion

Final remarks

Adriana Ceci & Viviana Giannuzzi

Please fill in the form below to access the material including speakers’ presentations shared during the webinar and the recording of the event

    Privacy* EU Regulation 2016/679 (GDPR) - It is authorized the processing of data contained in this form for internal use only. It is possible in every moment to asking for deletion.Read our privacy policy

    *: required fields

    Here below, you can freely access and download the material (e.g. speakers' presentations) provided during the last three training courses by submitting the form.

      Privacy* EU Regulation 2016/679 (GDPR) - Si autorizza al trattamento dei dati contenuti nel presente modulo al solo uso interno. È possibile in ogni momento chiederne la cancellazione.Leggi la nostra privacy policy

      *: campi obbligatori

      Di seguito, inviando il form, puoi accedere e scaricare gratuitamente il materiale (e.g. presentazioni dei relatori) fornito durante le ultime 3 edizioni del FTC.

      You can support our activities, including also the organisation of the Foresight Training Course, with a voluntary contribution that will help us keeping on our commitment and involvment in the research field. Even a small contribution can make the difference. Thank you!

      Course Scientific Committee

      Adriana Ceci | Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus
      Enrico Bosone | Società Italiana Attività Regolatorie
      Fedele Bonifazi | Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus
      Viviana Giannuzzi | Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus

      Organised by

      Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus

      icalUrl: - icalLink: iCal - webCalUrl: webcal:// - webCalLink: webcal - gCalUrl: - gCalLink: 0

      Subscribe To Our Newsletter

      to keep you up to date on our activities and initiatives

      La tua iscrizione non può essere convalidata.
      La tua iscrizione è avvenuta correttamente.

      We use Brevo as our marketing platform. By clicking below to submit this form, you are aware and accept that the information you have provided will be transferred to Brevo for treatment in accordance with their terms of use
      Utilizziamo Brevo come nostra piattaforma di marketing. Cliccando qui sotto per inviare questo modulo, sei consapevole e accetti che le informazioni che hai fornito verranno trasferite a Brevo per il trattamento conformemente alle loro condizioni d'uso

      You have Successfully Subscribed!

      Pin It on Pinterest

      Share This